TrianglePUBLICATIONS · 23233713
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2013 Feb 1
- First author
- San Miguel JF
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- San Miguel JF
- type
- Author
- name
- Schlag R
- type
- Author
- name
- Khuageva NK
- type
- Author
- name
- Dimopoulos MA
- type
- Author
- name
- Shpilberg O
- type
- Author
- name
- Kropff M
- type
- Author
- name
- Spicka I
- type
- Author
- name
- Petrucci MT
- type
- Author
- name
- Palumbo A
- type
- Author
- name
- Samoilova OS
- type
- Author
- name
- Dmoszynska A
- type
- Author
- name
- Abdulkadyrov KM
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- San Miguel JF
- type
- Author
- name
- Schlag R
- type
- Author
- name
- Khuageva NK
- type
- Author
- name
- Dimopoulos MA
- type
- Author
- name
- Shpilberg O
- type
- Author
- name
- Kropff M
- type
- Author
- name
- Spicka I
- type
- Author
- name
- Petrucci MT
- type
- Author
- name
- Palumbo A
- type
- Author
- name
- Samoilova OS
- type
- Author
- name
- Dmoszynska A
- type
- Author
- name
- Abdulkadyrov KM
- type
- Author
- bibliography ids
- nci-bib-9bd76b8f8aac631cfd12988d
- book metadata
- content sha256
- f453c975c8769c2df589510e8e61642d4bfaa530d30af3be7698032a3ddcf601
- document type
- citation
- dois
- 10.1200/JCO.2012.41.6180
- electronic publication date
- display
- 2012 Dec 10
- precision
- day
- year
- 2012
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:23233713
- immutable id
- pubmed:23233713@f453c975c8769c2df589510e8e61642d4bfaa530d30af3be7698032a3ddcf601
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 4
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 448-55
- volume
- 31
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 23233713
- provenance
- batch id
- 99e85dbb34a1a3011c9a
- provider
- NCBI PubMed ESummary
- record sha256
- 5c6e4ded0288e2727e1a14e0e3c3a5fc69c4e9bf26cb2dc5c93d0c66e99d9561
- response sha256
- 1f4a46dcee9da36f8f58fe356dce3f44a1b3004f404e9fb0184f4e08aed4acf2
- retrieved at
- 2026-09-09T23:46:52.860383+00:00
- publication date
- display
- 2013 Feb 1
- precision
- day
- year
- 2013
- publication types
- Comparative Study
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
Preserved source evidence · Not medical advice